Utama › Jangkitan Virus › Wilayah Columbia › Washington
Kajian klinikal Jangkitan Virus di Washington, DC
12 kajian untuk Jangkitan Virus sedang mencari peserta di lokasi dalam dan sekitar Washington (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Mengambil pesertaFasa 3
- Research Site, Washington D.C.
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Mengambil pesertaKajian pemerhatian
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
Mengambil pesertaKajian pemerhatian
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
Mengambil pesertaFasa 3
- Georgetown University Medical Center, Washington D.C.
- Jadestone Clinical Research, Silver Spring · 7 mi jauh
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
Mengambil pesertaFasa 3
- Georgetown University Medical Center, Washington D.C.
- Emerson Clinical Research Institute, Washington D.C.
- Jadestone Clinical Research, Silver Spring · 7 mi jauh
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
- George Washington University, Washington D.C.
Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Viral Infections in Healthy and Immunocompromised Hosts
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Genetic Studies of Chronic Active Epstein-Barr Disease
Mengambil pesertaKajian pemerhatian
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
Mengambil pesertaFasa 1
- Children's National Hospital, Washington D.C.
- National Institutes of Health (NIH), Bethesda · 7 mi jauh
Kajian Jangkitan Virus di bandar lain
- Boston, MA6 kajian
- Houston, TX6 kajian
- Hialeah, FL5 kajian
- Baltimore, MD5 kajian
- Atlanta, GA4 kajian
- Cincinnati, OH4 kajian
- Dallas, TX4 kajian
- Columbus, OH4 kajian
- Los Angeles, CA3 kajian
- Worcester, MA3 kajian
- Miami, FL3 kajian
- Tampa, FL3 kajian
Kajian lain di Washington
- Kanser (semua jenis)58 kajian
- Kanser Paru-paru Bukan Sel Kecil55 kajian
- Kanser Payudara46 kajian
- Kanser Metastatik43 kajian
- Kanser Paru-paru41 kajian
- Kanser Prostat38 kajian
- Obesiti33 kajian
- Kanser Kolorektal29 kajian
- Penyakit Kardiovaskular28 kajian
- Kanser Pundi Kencing26 kajian
- Leukemia Mieloid Akut24 kajian
- Kanser Ovari23 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.